KM Research Hub
← 返回论文库
无 KM 图 入排:符合 图源:可得 入排置信度 0.98

Development and Validation of an Artificial Intelligence Digital Pathology Biomarker to Predict Benefit of Long-Term Hormonal Therapy and Radiotherapy in Men With High-Risk Prostate Cancer Across Multiple Phase III Trials.

Andrew J Armstrong, Vinnie Y T Liu, Ramprasaath R Selvaraju, Emmalyn Chen, Jeffry P Simko, Sandy DeVries, Oliver Sartor, Howard M Sandler, Osama Mohamad, Huei-Chung Huang, Jacqueline Griffin, Rikiya Yamashita, Andre Esteva, Phuoc T Tran, Daniel E Spratt, John Hi Carson, Christopher Peters, Elizabeth Gore, Steve P Lee, Jedidiah M Monson, Mark E Augspurger, Ali El-Gayed, Joseph P Rodgers, Rana McKay, Todd Morgan, Felix Y Feng, Paul L Nguyen

J Clin Oncol 43(32) 3494-3504

PMID40239134
PMCIDPMC12228211
DOI10.1200/JCO.24.00365
发表日期2025-04-16
入排依据:原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
图像/No. at risk 复核:历史记录已完成可用 Figure 视觉审查,未识别 KM 曲线。
疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 3 张 PMC Figure,均未识别为 KM 图:Figure 1.:CONSORT/入组流程图;Figure 2.:森林图/亚组分析图;Figure 3.:森林图/亚组分析图。
摘要

摘要

PURPOSE: Long-term androgen deprivation therapy (ADT) improves survival in men with high-risk localized prostate cancer (PCa) receiving radiotherapy (RT). Predictive biomarkers are needed to guide ADT duration. METHODS: A multimodal artificial intelligence (MMAI)-derived predictive biomarker was trained for long-term (LT) versus short-term (ST) ADT using pretreatment digital prostate biopsy images and clinical data (age, prostate-specific antigen, Gleason, and T stage) from six NRG Oncology phase III randomized radiotherapy trials. The novel MMAI-derived biomarker was developed to predict the differential benefit of LT-ADT on the primary end point, distant metastasis (DM). MMAI predictive utility was validated on a seventh randomized trial, RTOG 9202 (N = 1,192), which randomly assigned men to RT + ST-ADT (4 months) versus RT + LT-ADT (28 months). Fine-Gray and cumulative incidence analyses for DM, and secondarily, death with DM, were performed. Deaths without DM were treated as competing risks. RESULTS: In the validation cohort (median follow-up, 17.2 years), LT-ADT significantly improved DM from 26% to 17% (subdistribution hazard ratio [sHR], 0.64 [95% CI, 0.50 to 0.82], P < .001). A significant biomarker-treatment predictive interaction was observed (P = .04) for DM, whereby MMAI biomarker-positive men (n = 785, 66%) had reduced DM with LT-ADT versus ST-ADT (sHR, 0.55 [95% CI, 0.41 to 0.73], P < .001), whereas no treatment benefit was observed for MMAI biomarker-negative men (n = 407; sHR, 1.06 [95% CI, 0.61 to 1.84], P = .84). The estimated 15-year DM risk difference between RT + LT-ADT and RT + ST-ADT was 14% in MMAI biomarker-positive men and 0% in MMAI biomarker-negative men. The MMAI biomarker was also prognostic for DM, irrespective of treatment (sHR, 2.35 [95% CI, 1.72 to 3.19], P < .001). CONCLUSION: To our knowledge, the MMAI model is the first validated predictive biomarker to guide ADT duration with RT in localized/locally advanced PCa. Approximately one third of men with high-risk PCa could safely be spared the additional 24 months of ADT and the associated morbidity.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。
其他 Figure(3,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Figure 1.CONSORT diagram for RTOG 9202 validation cohort *Deaths with distant metastasis are defined as death due to any cause with known distant metastasis. † Prostate cancer-specific deaths are defined as death due to prostate cancer, from protocol treatment complications/toxicities, and/or from unknown cause if a patient had a known metastasis, as per the NRG Oncology RTOG trial definition. ‡ Other-cause deaths are defined as “other deaths”, deaths related to a second primary tumor, or deaths from other treatment complications/toxicities, as per the NRG Oncology RTOG trial defined cause of death. Abbreviations: RT = radiotherapy; ST-ADT = short-term androgen deprivation therapy; LT-ADT = long-term androgen deprivation therapy; TURP = transurethral resection of the prostate
非 KM Figure
Figure 2.Cumulative incidence plots for the overall validation cohort and predictive biomarker subgroups for A) distant metastasis (DM) and B) death with distant metastases (DDM). Cumulative incidence estimates were compared using Gray’s test. Abbreviations: CI = confidence interval; RT = radiotherapy; LT-ADT = long-term androgen deprivation therapy; ST-ADT = short-term androgen deprivation therapy; Est. = estimated; DM = distant metastasis
非 KM Figure
Figure 3.Forest plot for treatment effect in primary, secondary, and exploratory endpoints within biomarker positive and negative groups for the overall validation cohort Events and N in parentheses reflect the number of events and patients in the LT-ADT treatment arm. Effect sizes are reported for RT + LT-ADT vs RT + ST-ADT from the appropriate model (Fine-Gray for DM, DDM, and PCSM; Cox Proportional Hazards for MFS and OS). Abbreviations: (s)HR = (subdistribution) hazard ratio; CI = confidence interval; p = p-value; LT-ADT = long-term androgen deprivation therapy; DM = distant metastasis; DDM = death with distant metastasis; PCSM = prostate cancer-specific mortality; MFS = metastasis-free survival; OS = overall survival
非 KM Figure